Adjuvant Development Program

NIAID/DAIT佐剂开发项目支持开发新的候选疫苗佐剂，刺激先天免疫反应，以防止NIAID A、B和C类病原体的感染。目前，氢氧化铝/磷酸铝（明矾）是美国唯一获准用于一般人类使用的佐剂。由于明矾不是一种普遍有效的佐剂，因此需要寻找其他佐剂，以刺激对各种微生物更广泛有效和安全的反应。符合支持条件的候选疫苗佐剂必须：1)先前被确定为安全的，2)通过激活先天免疫系统起作用，3)具有记录的佐剂作用机制，4)成为产品开发计划的一部分，将在5年的合同履行期内显著推进产品，5)在可能的情况下，能够在体内动物模型的致病性攻击中安全地增强疫苗对NIAID a， B和C类病原体的效力。

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants that stimulate innate immune responses to protect against infection by NIAID Category A, B, and C Pathogens. Currently, aluminum hydroxide/aluminum phosphate (alum) is the only licensed adjuvant for general human use in the United States. Because alum is not a universally effective adjuvant, additional adjuvants are sought that can stimulate more broadly effective and safe responses to a wide variety of microorganisms. Candidate vaccine adjuvants eligible for support must: 1) be previously identified and characterized as safe, 2) function by activating the innate immune system, 3) have a documented mechanism of action for the adjuvant, 4) be part of a Product Development Plan that will significantly advance the product within the 5 year period of contract performance, and 5) when possible, be able to augment vaccine efficacy safely against an NIAID Category A, B, and C Pathogen upon pathogenic challenge in an in vivo animal model.